SCHEMBL3367290

SCHEMBL3367290

CCOC(=O)Nc1nc(NC(=O)OC)nc(NC(=O)OC)n1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.49
ALOX15 P16050 1/20 0.47
KDM4E B2RXH2 2/20 0.46
GLA P06280 2/20 0.46
POLB P06746 1/20 0.46
ALDH1A1 P00352 5/20 0.45
CYP1A2 P05177 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
HPGD P15428 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
RECQL P46063 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
LMNA P02545 1/20 0.42
HSD17B10 Q99714 1/20 0.41
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3364492 1.00 KMT2A (0.49) KMT2AALOX15KDM4EGLAPOLB
SCHEMBL3363746 0.94 KMT2A (0.53) KMT2AKDM4EGLAPOLBALDH1A1
SCHEMBL6682837 0.88 ALOX15 (0.46) KMT2AALOX15KDM4EGLAPOLB
SCHEMBL2910688 0.85 LMNA (0.47) KMT2AALOX15KDM4EPOLBALDH1A1
SCHEMBL3365339 0.85 SMN1; SMN2 (0.46) KMT2AKDM4EGLAPOLBALDH1A1
SCHEMBL3366859 0.85 SMN1; SMN2 (0.46) KMT2AKDM4EGLAPOLBALDH1A1
SCHEMBL11795513 0.83 POLB (0.48) KMT2AKDM4EGLAPOLBALDH1A1
SCHEMBL6675218 0.82 TSHR (0.56) KMT2AKDM4EGLAALDH1A1CYP1A2
SCHEMBL2903601 0.82 RAB9A (0.51) KMT2AKDM4EGLAALDH1A1CYP1A2
SCHEMBL2906397 0.82 RAB9A (0.51) KMT2AKDM4EGLAALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1440065-B1 METHOD FOR PREPARING ALKOXYCARBONYLAMINO-TRIAZINES BASF SE (DE) 2010-10-06 EP disclosed
US-7371856-B2 Preparation of alkoxycarbonylaminotriazines BASF AKTIENGESELLSCHAFT (DE) 2008-05-13 US disclosed
US-20070083047-A1 Preparation of Alkoxycarbonylaminotriazines BASF AKTIENGESELLSCHAFT (DE) 2007-04-12 US disclosed
US-7169923-B2 Method for preparing alkoxycarbonylamino-triazines BASF AKTIENGESELLSCHAFT (DE) 2007-01-30 US disclosed
US-20040249149-A1 Method for preparing alkoxycarbonylamino-triazines BASF AKTIENGESELLSCHAFT (DE) 2004-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040249149-A1 Method for preparing alkoxycarbonylamino-triazines ADH1C, PNMT, TET2 KMT2A 38/4885ALOX15 2345/4885KDM4E 541/4885
US-20070083047-A1 Preparation of Alkoxycarbonylaminotriazines ADH1C, TET2, PNMT KMT2A 85/4885ALOX15 3714/4885KDM4E 354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.